Log in
Automation of genomic data analysis has become essential. High-throughput sequencing technologies are producing data faster than can be managed and interpreted, meaning that much biomedical information remains unused.
Research led by Attwood introduced a unique method for protein sequence characterisation and a derived database of diagnostic protein signatures (PRINTS). This led directly to the development of a new database (InterPro), now routinely used to annotate the world's largest protein sequence archive (UniProt), and complete genomes and metagenomes. The databases and their search tools have been exploited in the private sector (including SMEs and multi-national pharmaceutical and agrichemical companies), generating workflows that have yielded candidate drug targets and provided insights into disease mechanisms.
MicroRNAs are a class of non-protein-coding RNA genes that regulate the expression of protein-coding mRNAs in animals and plants. Researchers at the University of Manchester (UoM) have developed a microRNA database (miRBase) which has become an essential resource for researchers both in academia and the pharmaceutical industry. The database is the central global repository for all published microRNA sequences and annotation.
miRBase data enables production of novel experimental kits and resources (including microRNA qPCR assays and microarrays) by companies including ABI, Invitrogen, Sigma-Aldrich and Exiqon. Tools produced by these companies underpin experimental microRNA research across academic and industrial settings, which benefit product development, drug discovery and clinical research. Exiqon reported more than 110 million DKK in revenue from their life science business in 2012, with main product lines involving microRNAs.
Research at the University of Manchester (UoM) has changed the landscape of medical care and research in fungal infections internationally. The impacts include: the world's first commercialised molecular diagnostic products for aspergillosis and Pneumocystis pneumonia (£10m investment); pivotal contributions to the preclinical development (£35m investment), clinical developments and registrations of 3 new antifungals with combined market share of ~$2 billion; one (voriconazole, 2012 sales >$750m worldwide) now first line therapy for invasive aspergillosis with improved survival of 15-20%; and internationally validated methods to detect azole resistance in Aspergillus (an emerging problem partly related to environmental spraying of azole fungicides for crop protection).
15m people have a stroke each year worldwide. In England alone, stroke generates direct care costs of £3bn and a wider economic burden of £8bn. Service users report high levels of unmet need in relation to cognitive dysfunction (e.g. concentration). Improving cognition was the number one priority agreed by users and providers (James Lind Alliance, Lancet Neurology 2012). Research led by the University of Manchester (UoM) underpins recommendations in several recent clinical guidelines for stroke management and rehabilitation in the UK and internationally. Our 2012 aphasia trial and qualitative study made key contributions to the recommendations in the recent NICE (2013) and Intercollegiate Stroke Working Party (2012) guidelines. UoM-led Cochrane reviews (e.g., neglect, apraxia, perception) have directly influenced recommendations in guidelines produced by the Scottish Intercollegiate Guidelines Network, the European Stroke Organization and the Australian National Stroke Foundation.
RTT (Real Time Tomography) scanning systems for airport baggage are becoming increasingly important due to growing air traffic and greater security concerns. Prior to our research, Rapiscan, a leading producer of baggage scanners, had been unable to make full use of the hardware in their latest generation of scanner prototypes. Our novel theory and image reconstruction algorithms are now a core part of a commercially successful 3D scanner that is significantly faster and more accurate than previous generations. The two models, RTT80 and large RTT110, have been approved by regulatory authorities and have already been field trialled at Manchester Airport and deployed at Seattle airport, with further US$20m orders placed.
The research and impact described herein was flagged in the citation for the UoM's 2013 Queen's Anniversary Prize for Higher and Further Education for its work in imaging techniques to support advanced materials and manufacturing.
Development of the human cell GADD45a assay enabled accurate identification of carcinogens in vitro, with a low rate of misleading positives. Through the spin-out company Gentronix, this research is reducing costs to industry and decreasing the use of animals in research. Industrial collaboration has enabled commercial adoption of the technology in many sectors. With a 10-fold increase in orders in 2012 versus 2008, Gentronix is a profitable business employing 17 people and with an annual turnover of £1.88m. During 2008-12, Gentronix released a series of new products, established testing services, and signed a product license agreement with GlaxoSmithKline. More than 100 companies worldwide are using Gentronix kits, including pharmaceutical, agricultural and health and beauty companies, along with manufacturers of food flavourings and household goods. The Gentronix assay is currently being reviewed by the European Centre for the Validation of Alternative Methods.
Falls are a common (30-40% >65 year olds fall each year) and important age-related health problem costing the NHS and social care >£5.6m each day. University of Manchester research has contributed to reducing the burden of falls worldwide.
We demonstrated that falls are better predictors of fracture than bone mineral density. We developed an effective intervention, reducing falls amongst older people by 30%; identified barriers to service use, and approaches to increasing uptake and adherence; and developed a fear of falling instrument (FES-I), now translated into 30+ languages and widely used in clinical practice.
By 2012, 54% NHS Trusts used training programmes based on our research. It moulded service provision nationally and internationally, changing the emphasis of how falls prevention services are presented, from "reducing risk" to "improving/maintaining independence".
WHO estimates that 600 million school-age children need deworming treatment and preventive intervention.
The University of Manchester (UoM) Immunology Group delivered an educational programme on the immune response and biology of parasitic worm infections in areas where worm infections are most prevalent, including Uganda and Pakistan, and with UK immigrant communities.
International benefits include health worker and educator training, which is critical for improving the understanding of worm infection and distribution of health education messages to endemic communities. Nationwide engagement activities provided immigrant communities and school pupils with improved awareness of global health issues and a greater understanding of immunology, and have inspired some participants to pursue careers in science.
The University of Brighton's sustained musculoskeletal research programme has, through the development of novel standardised data collection tools, improved data capture, communication, policy and business planning at local practitioner level and at organisational/regulatory body levels (e.g. Physio First, the private physiotherapy practitioner group of the Chartered Society of Physiotherapy (CSP) UK and the General Osteopathic Council (GOsC)). Secondly, research findings from a study exploring patients' expectations have significantly informed the recent revision of the GOsC's osteopathic practice standards and a new revalidation scheme for osteopaths. Thirdly, as a result of studies identifying research priorities for the physiotherapy profession, changes have occurred in the direction and focus of research funding applied by the CSP's charitable trust.
About 18% of UK electric supply is provided by 14 graphite-moderated Advanced Gas-cooled Reactors (AGRs) and 1 Pressurised Water Reactor (PWR). The AGRs are graphite-moderated, generic in design and the nuclear regulator is concerned that a common safety related fault could lead to immediately shutdown of all AGRs. The development of novel techniques at Manchester has allowed the continued operation helping the operators to establish an expected seven-year life extensions for all AGRs. For the plant operators this represents a potential income of £2.5bn per annum, avoid 30m tonnes CO2 pa and generate supply chain income within the UK of £650m pa and create or protect 2000 jobs.